Aegis initiated coverage on shares of Kintara Therapeutics (NASDAQ:KTRA) in a research report report published on Monday, The Fly reports. The firm issued a buy rating and a $6.00 price target on the stock.
Shares of NASDAQ KTRA opened at $1.60 on Monday. Kintara Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.95.
Kintara Therapeutics Company Profile
Further Reading: Overbought
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.